Emerging drugs in pancreatic cancer

Bibliography

• EVANS DB, ABBRUZZESE JL, WILLETT CG: Cancer of the pancreas. In: Cancer: Principles and Practice of Oncology DeVita VTJ, Hellman S, Rosenberg SA (Eds.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2000:1126–1161.
   Google Scholar
• BRAMHALL SR, ALLUM WH, JONES AG, ALLWOOD A, CUMMINS C, NEOPTOLEMOS JP: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. &mg. (1995) 82(1):111–115.
   Web of Science ®Google Scholar
• BRAMHALL SR, DUNN J, NEOPTOLEMOS JP: Epidemiology of pancreatic cancer. In: The Pancreas. Beger HG, Warshaw A, Carr-Locke DL (Eds), Blackwell Scientific, Boston, MA, USA (1998):889–906.
   Google Scholar
• FERNANDEZ E, LA VECCHIA C, PORTA M, NEGRI E, LUCCHINI F, LEVI F: Trends in pancreatic cancer mortality in Europe, 1955-1989. Int. J. Cancer (1994) 57(6):786–792.
   PubMed Web of Science ®Google Scholar
• JEMAL A, THOMAS A, MURRAY T, THUN M: Cancer statistics, 2002. CA Cancer J. Clia (2002) 52(1):23–47.
   PubMed Web of Science ®Google Scholar
• PARKIN DM, BRAY Fl, DEVESA SS: Cancer burden in the year 2000. The global picture. Eur. J. Cancer (2001) 37\(Suppl. 8):S4–S66.
   Google Scholar
• FERLAY J, BRAY F, PISANI P, PARKIN DM: GLOBOSCAN 2000: Cancer incidence, mortality and prevalence worldwide, version LOJARC Press. Cancer Base (2001).
   Google Scholar
• LOWENFELS AB, MAISONNEUVE P, CAVALLINI G et al: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl. I Med. (1993) 328:1433–1437.
   PubMed Web of Science ®Google Scholar
• LOWENFELS AB, MAISONNEUVE P, DIMAGNO EP et al: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Nati Cancer Inst. (1997) 89(6):442–446.
   PubMed Web of Science ®Google Scholar
• MALKA D, HAMMEL P, MAIRE F et al.: Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut (2002) 51(6):849–852.
   PubMed Web of Science ®Google Scholar
• WONG T, HOWES N, THREADGOLD J et al: Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology (2001) 1(5):486–509.
   PubMed Web of Science ®Google Scholar
• COUGHLIN SS, CALLE EE, PATEL AV, THUN MJ: Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control (2000) 11(10):915–923.
   PubMed Web of Science ®Google Scholar
• HARNACK LJ, ANDERSON KE, ZHENG W, FOLSOM AR, SELLERS TA, KUSHI LH: Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Women's Health Study. Cancer Epidenhol Biomarkers Prey (1997) 6(12):1081–1086.
   PubMed Web of Science ®Google Scholar
• LOWENFELS AB, MAISONNEUVE P, WHITCOMB DC, LERCH MM, DIMAGNO EP: Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. IA/VIA (2001) 286(2):169–170.
   Web of Science ®Google Scholar
• HAYCOX A, LOMBARD M, NEOPTOLEMOS J, WALLEY T: Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. Aliment. Pharmacol Thar. (1998) 12(10):937–948.
   PubMed Web of Science ®Google Scholar
• MAGEE CJ, GREENHALF W, HOWES N, GHANEH P, NEOPTOLEMOS JP: Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. Surg. Oncol (2001) 10(1-2):1–23.
   PubMed Web of Science ®Google Scholar
• EDIS AJ, KIERNAN PD, TAYLOR WF: Attempted curative resection of ductal carcinoma of the pancreas. Review of Mayo Clinic Experience, 1951-1975. Mayo Clin. Proc. (1980) 55:531–536.
   PubMed Web of Science ®Google Scholar
• JANES RH, NIEDERHUBER JE, CHMIEL JS et al: National patterns of care for pancreatic cancer. Results of a survey by the commission on cancer. Ann. Surg. (1996) 223(3):261–272.
   PubMed Web of Science ®Google Scholar
• MANABE T, OHSHIO G, BABA N et al: Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer (1989) 64:1132–1137.
   PubMed Web of Science ®Google Scholar
• BAUMEL H, HUGUIER M, MANDERSCHEID JC, FABRE JM, HOURY S, FAGOT H: Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br. J. Surg. (1994) 81(1):102–107.
   PubMed Web of Science ®Google Scholar
• HALLER DG: Chemotherapy for advanced pancreatic cancer. Intl. Radiat. Oncol Phys. (2003) 56\(Suppl. 4):16–23.
   PubMed Web of Science ®Google Scholar
• Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. Oncol (1986) 4(12):1794–1798.
   Google Scholar
• BURRIS HAI, MOORE JA, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Chit. Oncol (1997) 15:2403–2413.
   PubMed Web of Science ®Google Scholar
• ••This landmark randomised trialestablished gemcitabine as the standard first-line therapy for advanced PDA.
   Google Scholar
• OSTER MW, GRAY R, PANASCI L, PERRY MC: Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer (1986) 57(1):29–33.
   Google Scholar
• PLUNKETT W, HUANG P, GANDHI V: Preclinical characteristics of gemcitabine. Anticancer Drugs (1995) 6(Suppl.):7–13.
   PubMed Web of Science ®Google Scholar
• CARMICHAEL J, FINK U, RUSSELL RC et al: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer (1996) 73(1):101–105.
   Google Scholar
• CASPER ES, GREEN MR, KELSEN DP et al: Phase II trial of gemcitabine (2',2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs (1994) 12(1):29–34.
   PubMed Web of Science ®Google Scholar
• HUANG P, CHUBB S, HERTEL LW, GRINDEY GB, PLUNKETT W: Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. (1991) 51(22):6110–6117.
   PubMed Web of Science ®Google Scholar
• LOUVET C, LABIANCA R, HAMMEL P et al: Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non resectable pancreatic adenocarcinoma: interim results of the GERCOR/GISCAD intergroup phase III. Proc. Am. Soc. Clin. Oncol (2003) 22:250 (Abstract).
   PubMed Web of Science ®Google Scholar
• ••Preliminary results of a randomised trialsuggesting that gemcitabine plus oxaliplatin could become a new standard for first-line therapy of advanced PDA.
   Google Scholar
• TOUROUTOGLOU N, GRAVEL D, RABER MN, PLUNKETT W, ABBRUZZESE JL: Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann. Oncol (1998) 9(9):1003–1008.
   PubMed Web of Science ®Google Scholar
• TEMPERO M, PLUNKETT W, RUIZ VH et al: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. Gila Oncol. (2003) 21(18):3402–3408.
   Web of Science ®Google Scholar
• •A basis for considering fixed dose rate Infusion as a potential new standard for administration of gemcitabine.
   Google Scholar
• CARTER SK, COMIS RL: The integration of chemotherapy into a combined modality approach for cancer treatment VI. Pancreatic adenocarcinoma. Cancer Treat. Rev (1975) 2(3):193–214.
   PubMed Web of Science ®Google Scholar
• DUCREUX M, ROUGIER P, PIGNON J-P et al: A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol (2002) 13:1185–1191.
   PubMed Web of Science ®Google Scholar
• •A large randomised trial showing that 5-FU is ineffective, and that the benefit conferred by the addition of cisplatin is counterbalanced by increased toxicity.
   Google Scholar
• GLIMELIUS B, HOFFMAN K, SJODEN PO et al: Chemotherapy improves survival and quality of life in advanced pancreatic and binary cancer. Ann. Oncol (1996) 7(6):593–600.
   PubMed Web of Science ®Google Scholar
• •This study established palliative chemotherapy as a standard over best supportive care in advanced PDA.
   Google Scholar
• MALLINSON CN, RAKE MO, COCKING JB et al: Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomized, multicentre trial. BE Med. J. (1980) 281(6255):1589–1591.
   PubMed Web of Science ®Google Scholar
• PALMER KR, KERR M, KNOWLES G, CULL A, CARTER DC, LEONARD RC: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. Surg. (1994) 81:882–885.
   PubMed Web of Science ®Google Scholar
• CULLINAN S, MOERTEL CG, WIEAND HS et al: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer (1990) 65:2207–2212.
   PubMed Web of Science ®Google Scholar
• AUERBACH M, WAMPLER GL, LOKICH JJ, FRYER D, FRYER JG, AHLGREN JD: Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study. Ann. Oncol (1997) 8(5):439–444.
   PubMed Web of Science ®Google Scholar
• MAISEY N, CHAU I, CUNNINGHAM D et al: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. Clin. Oncol (2002) 20(14):3130–3136.
   Web of Science ®Google Scholar
• LOU VET C, BEERBLOCK K, DE GRAMONT A et al: High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study. Eur. J. Cancer (1993) 29A:1217 (letter).
   Google Scholar
• MATANO E, TAGLIAFERRI P, LIBROIA A et al.: Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented Phase II study. Br. J. Cancer (2000) 82(11):1772–1775.
   Google Scholar
• OETTLE H, PELZER U, HOCHMUTH K et al: Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anticancer Drugs (1999) 10(8):699–704.
   PubMed Web of Science ®Google Scholar
• RAUCH DP, MAURER CA, AEBI S et al.: Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology (2001) 60(1):43–48.
   PubMed Web of Science ®Google Scholar
• BERLIN JD, CATALANO P, THOMAS JP, KUGLER JW, HALLER DG, BENSON AB: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.1 Clin. Oncol. (2002) 20(15):3270–3275.
   Google Scholar
• BERLIN JD, ALBERTI DB, ARZOOMANIAN RZ et al: A Phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest. New Drugs (1998) 16(4):325–330.
   PubMed Web of Science ®Google Scholar
• POPLIN E, ROBERTS J, TOMBS M, GRANT S, RUBIN E: Leucovorin, 5-fluorouracil, and gemcitabine: a Phase I study. Invest. New Drugs (1999) 17(1):57–62.
   Google Scholar
• BURCH PA, BLOCK M, SCHROEDER G et al: Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. Clin. Cancer Res. (2000) 6(9):3486–3492.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J. Clin. Oncol (1998) 16:301–308.
   PubMed Web of Science ®Google Scholar
• EL-RAYES BE ZALUPSKI MM, SHIELDS AF et al: Phase II study of gemcitabine, cisplatin and infusional fluorouracil in advanced pancreatic cancer. Clin. Oncol. (2003) 21:2920–2925.
   Web of Science ®Google Scholar
• RENI M, PASSONI P, PANUCCI MG et al.: Definitive results of a Phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.Oncol (2001) 19(10):2679–2686.
   Google Scholar
• PAZDUR R, HOFF PM, MEDGYESY D, ROYCE M, BRITO R: The oral fluorouracil prodrugs. Oncology (Hunting) (1998) 12(10, Suppl. 7):48–51.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA T, UTOH M, SAWADA N et al.: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol (1998) 55(7):1091–1097.
   PubMed Web of Science ®Google Scholar
• MIWA M, URA M, NISHIDA M et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer (1998) 34(8):1274–1281.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT TH, COHN A, VARKEY JA et al: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol (2002) 20(1):160–164.
   PubMed Web of Science ®Google Scholar
• SCHEITHAUER W, KORNEK GV, RADERER M et al: Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol (2003) 21(7):1307–1312.
   PubMed Web of Science ®Google Scholar
• TWELVES C, HARPER P, VAN CUTSEM E et al. A phase III trial (SO14796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol (1999) 18:263a.
   Google Scholar
• O'SHAUGHNESSY J, MILES D, VUKELJA S et al.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol (2002) 20(12):2812–2823.
   PubMed Web of Science ®Google Scholar
• UENO H, OKADA S, OKUSAKA T, IKEDA M, KURIYAMA H: Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncology (2002) 62(3):223–227.
   PubMed Web of Science ®Google Scholar
• FELIU J, LOPEZ ALVAREZ MP, JARAIZ MA et al: Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group. Cancer (2000) 89(8):1706–1713.
   PubMed Web of Science ®Google Scholar
• COLUCCI G, GIULIANI F, GEBBIA V et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer (2002) 94(4):902–910.
   PubMed Web of Science ®Google Scholar
• HEINEMANN V, QUIETZSCH D, GIESELER F et al.: A Phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancratic carcinoma. Proc. Am. Soc. Clin. Oncol (2003) 22:250 (Abstract).
   Google Scholar
• DUCREUX M, MITRY E, OULD-KACI M et al: Randomized Phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann. Oncol (2004) 15(3):467–473.
   PubMed Web of Science ®Google Scholar
• CONROY T, PAILLOT B, FRANCOIS E et al.: Irinotecan (CPT-11), oxaliplatin (L-OHP) plus 5-FU/leucovorin (5FU/LV) as first line chemotherapy in patients (pts) with advanced pancreatic adenocarcinoma (APA). Proc. Am. Soc. Clin. aryl (2002) 21:147.
   Google Scholar
• FAIVRE S, LE CHEVALIER T, MONNERAT C et al.: Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann. Oncol (2002) 13(9):1479–1489.
   PubMed Web of Science ®Google Scholar
• LOUVET C, ANDRE T, LLEDO G et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter Phase II study.' Clin. Oncol (2002) 20(6):1512–1518.
   Google Scholar
• ALBERTS SR, TOWNLEY PM, GOLDBERG RM et al: Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II study. Ann. Oncol (2003) 14(4):580–585. JEFFERY M et al: A randomized Phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer (2003) 22:251.
   PubMed Web of Science ®Google Scholar
• STEHLIN JS, GIOVANELLA BC, NATELSON EA et al: A study of 9-nitrocamptothecin (RFS-2000) in
   Google Scholar
• •A Phase I trial suggesting that rubitecan may have promising efficacy in advanced PDA.
   Google Scholar
• KONSTADOULAKIS MM, ANTONAKIS PT, TSIBLOULIS BG et al: A Phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother. Pharmacol (2001) 48(5):417–420.
   PubMed Web of Science ®Google Scholar
• D'ADAMO D, HAMMOND L, DONEHOWER R et al: Final results of a Phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2001) 20:134 (Abstract).
   Google Scholar
• O'REILLY EM, ABOU-ALFA GK, HOFF P et al. DX-8951f in advanced pancreatic cancer (APC). 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 138 (Abstract).
   Google Scholar
• VEITIA R, DAVID S, BARBIER P et al:Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel. BE J. Cancer (2000) 83(4):544–549.
   Web of Science ®Google Scholar
• ROUGIER P, ADENIS A, DUCREUX M et al A Phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer (2000) 36:1016–1025.
   PubMed Web of Science ®Google Scholar
• ANDROULAKIS N, KOUROUSIS C, DIMOPOULOS MA et al: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter Phase II study. I Clin. Oncol (1999) 17(6):1779-1785. OKADA S, SAKATA Y, MATSUNO S et al: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br. J. Cancer (1999) 80(3-4):438-443. LUTZ MP, DUCREUX M, WAGENER T et al. Docetaxeligemcitabine or docetaxel/ cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group. Proc. Am. Soc. Clin. Oncol (2002) 21:125 (Abstract). SCHNEIDER BP, GANJO0 KN, SEITZ DE et al: Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology (2003) 65(3):218–223.
   Web of Science ®Google Scholar
• OKADA S, SAKATA Y, MATSUNO S et al.: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br. J. Cancer (1999) 80(3-4):438–443.
   PubMed Web of Science ®Google Scholar
• LUTZ MP, DUCREUX M, WAGENER T et al: Docetaxel/gemcitabine or docetaxel/ cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group. Proc. Am. Soc. Clin. Oncol. (2002) 21:125 (Abstract).
   Google Scholar
• SCHNEIDER BP, GANJOO KN, SEITZ DE et al.: Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology (2003) 65(3):218–223.
   PubMed Web of Science ®Google Scholar
• SHERMAN WH, FINE RL: Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology (2001) 60(4):316–321.
   PubMed Web of Science ®Google Scholar
• STATHOPOULOS GP, MAVROUDIS D, TSAVARIS N et al: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a Phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol (2001) 12(1):101–103.
   PubMed Web of Science ®Google Scholar
• KURTZ JE, ANDRES E, NATARAJAN-AME S, NOEL E, DUFOUR P: Oral chemotherapy in colorectal cancer treatment: review of the literature. Eur. J. Intern. Med. (2003) 14(1):18–25.
   PubMedGoogle Scholar
• KRALIDIS E, AEBI S, FRIESS H, BUCHLER MW, BORNER MM: Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann. Oncol (2003) 14(4):574–579.
   PubMed Web of Science ®Google Scholar
• VAN LAETHEM J-L, VAN MAELE P, POLUS M et al. Raltitrexed (Tomudex) and gemcitabine (Gemzar) in advanced pancreatic carcinoma: a Belgian multicentre phase II study. Proc. Am. Soc. OM. Oncol (2002) 21:137 (Abstract).
   Google Scholar
• MILLER KD, PICUS J, BLANKE C et al:Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann. Oncol (2000) 11(1):101–103.
   PubMed Web of Science ®Google Scholar
• KINDLER HL, DUGAN W, HOCHSTER H, STRICKLAND D, JACOBS A, JOHN WJ: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with permetrexed/ gemcitabine. Proc. Am. Soc. Clin Oricol (2002) 21:125 (Abstract).
   Google Scholar
• SMITH D, GALLAGHER N: A Phase II/ III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. Eur. J. Cancer (2003) 39(10):1377–1383.
   Google Scholar
• MOORE MJ, HAMM J, DANCEY J et al: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Clin. Oncol (2003) 21(17):3296–3302.
   Web of Science ®Google Scholar
• •This randomised trial showed that the MMPI BAY12–9566 was inferior to gemcitabine in advanced PDA.
   Google Scholar
• BRAMHALL SR, SCHULZ J, NEMUNAITIS J, BROWN PD, BAILLET M, BUCKELS JA: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. BE J. Cancer (2002) 87(2):161–167.
   Web of Science ®Google Scholar
• VAN CUTSEM E, KARASEK P, OETTLE H et al: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2002) 21:130 (Abstract).
   Google Scholar
• HURWITZ HI, AMADO R, PRAGER D: Phase I pharmacokinetic trial of the farnesyl transferase inhibitor 5CH66366 plus gemcitabine in advanced cancers. Proc. Am. Soc. Clin. Oncol (2000) 19:717 (Abstract).
   PubMed Web of Science ®Google Scholar
• LOBELL RB, OMER CA, ABRAMS MT et al.: Evaluation of farnesykprotein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. (2001) 61(24):8758–8768.
   PubMed Web of Science ®Google Scholar
• KOKAWA A, KONDO H, GOTODA T et al: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer (2001) 91(2):333–338.
   PubMed Web of Science ®Google Scholar
• XIONG HQ, DU M, WOLFF RA et al: Pharamcology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2002) 21:113 (Abstract).
   Google Scholar
• SMITH SE, BURRIS HA, LOEHRER PJ et al.: Preliminary report of a Phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:374 (Abstract).
   PubMed Web of Science ®Google Scholar
• LIPTON A, HARVEY H, WITTERS L, KERR S, LEGORE K, CAMPBELL C: Phase II trial of gemcitabine + irinotecan + celecoxib in pancreatic cancer. 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 153 (Abstract).
   Google Scholar
• SAFRAN H, RAMANATHAN R, SCHWARTZ J et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc. Am. Soc. Clin. Oncol (2001) 20:130a.
   Google Scholar
• ABBRUZZESE JL, ROSENBERG A, XIONG Q et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc. Am. Soc. Chit. Oncol (2001) 20:130 (Abstract).
   Google Scholar
• DRAGOVICH T, PATNAIK A, ROWINSKY EK et al: A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies. Proc. Am. Soc. Clin. OncoL (2003) 22:223 (Abstract).
   Google Scholar
• MORGAN JA, BUKOWSKI RIVI, XIONG H et al.: Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:197 (Abstract).
   Google Scholar
• KINDLER HL, ANSARI R, LESTER E et al: Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advnaced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol (2003) 22:259 (Abstract).
   PubMed Web of Science ®Google Scholar
• •Interim but promising results for bevacizumab-gemcitabine combination in advanced PDA.
   Google Scholar
• KINDLER HL, FRIBERG G, STADLER WM et al. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: interim results of an ongoing Phase II trial from the University of Chicago Phase II consortium. 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 86 (Abstract).
   Google Scholar
• RYAN DP, EDER JP, WINKELMANN J et al.: Pharmacokinetic and pharmacodynamic Phase I study of PS-431 and gemcitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21:95a.
   Web of Science ®Google Scholar
• RICHARDS DA, WAERHOUSE DM, WAGENER DTH et al: Randomized, double-blind, placebo-controlled Phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994+G) versus placebo plus gemcitabine (P+G) in the treatment of patients with advanced pancreatic cancer (APC). Proc. Am. Soc. Oncol (2002) 21:162a.
   Google Scholar
• FERRY DR, DEAKIN M, BADDELEY J et al.: A Phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann. Oncol (2000) 11(9):1165–1170.
   PubMed Web of Science ®Google Scholar
• BURCH PA, ALBERTS SR, SCHROEDER MT et al. Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma (ACA): a North Central Cancer Treatment Group (NCCTG) Phase II study. Proc. Am. Soc. Clin. Oncol (2003) 22:259.
   Google Scholar
• HANNA S, CHUNG T, HECHT JR et al.: Safety and efficacy of TNFerade in unresectable locally advanced pancreatic cancer: results of the first two cohorts of a dose escalating study. 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 84 (Abstract).
   Google Scholar
• ICLI F, AKBULUT H, UTKAN G et al: Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:286 (Abstract).
   Google Scholar
• •Intriguing findings suggesting that LMWH may have efficacy in advanced PDA when combined with chemotherapy.
   Google Scholar
• GJERTSEN MK, BAKKA A, BREIVIK J et al.: Vaccination with mutant is peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet (1995) 346(8987):1399–1400.
   PubMed Web of Science ®Google Scholar
• CHANG DZ, ABOU-ALFA GK, O'REILLY EM et al.: Vaccination of pancreatic cancer patients against mutated K-ras. Proc. Am. Soc. Clin. OncoL (2003) 22:285 (Abstract).
   Google Scholar
• HAMILTON J, BEHRENS RJ, ACHTAR M et al: An adjuvant Phase II pilot trial of mutant is peptide vaccine in stage II and III pancreatic and Dukes C and D colorectal cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:186 (Abstract).
   Google Scholar
• GAUDERNACK G, BUANES T, MEO M et al.: Clinical trials of a peptide based vaccine targeting telomerase. Proc. Am. Soc. Oncol (2003) 22:166 (Abstract).
   Google Scholar
• BRETT BT, SMITH SC, BOUVIER CV et al: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. OncoL (2002) 20(20):4225–4231.
   PubMed Web of Science ®Google Scholar
• •Promising results suggesting a potential therapeutic role for anti-gastrin antibodies In advanced PDA.
   Google Scholar
• TALAMONTI MS, CATALANO PJ, VAUGHN DJ et al: Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J. Clin. OncoL (2000) 18(19):3384–3389.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG, CHILDS DS, REITEMEIER RJ, COLBY MY, HOLBROOK MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet (1969) 2:865–867.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG, FRYTAK S, HAHN RG et al: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluorouracifl, and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer (1981) 48: 1705–1710.
   Google Scholar
• MEHTA VK, POEN JC, FORD JM et al: Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am. J. Clin. Oncol (2001) 24(2):155–159.
   PubMed Web of Science ®Google Scholar
• BOZ G, DE PAOLI A, INNOCENTE R et al.: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int. Radiat. Oncol Biol. Phys. (2001) 51(3):736–740.
   PubMed Web of Science ®Google Scholar
• LUDERHOFF EC, GONZALEZ GD, BAKKER P: Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil. Radiother. OncoL (1996) 40(3):241–243.
   PubMed Web of Science ®Google Scholar
• PROTT FJ, SCHONEKAES K, PREUSSER P et al: Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the
   Google Scholar
• •• pancreas: results of a feasibility study. Br. J. Cancer (1997) 75(4):597–601.
   PubMed Web of Science ®Google Scholar
• PENBERTHY DR, RICH TA, SHELTON CH 3rd, ADAMS R, MINASI JS, JONES RS: A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer. Ann.Oncol. (2001) 12(5):681–684.
   PubMed Web of Science ®Google Scholar
• SHINCHI H, TAKAO S, NOMA H et al.: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int. J. Radiar Oncol Biol. Phys. (2002) 53(1):146–150.
   PubMed Web of Science ®Google Scholar
• •A randomised trial suggesting that 5-FU-based CRT may be superior to no CRT in locally advanced PDA.
   Google Scholar
• OSTI ME COSTA AM, BIANCIARDI F et al.: Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a Phase II study. Tumori (2001) 87(6):398–401.
   PubMed Web of Science ®Google Scholar
• SAITO Y, MILROSS CG, HITTELMAN WN et al.: Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction. Int. Radiat. Oncol Biol. Phys. (1997) 38(3):623–631.
   PubMed Web of Science ®Google Scholar
• RICH TA, HARRIS J, ABRAMS R et al.: A Phase II study of external irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: a preliminary report of RTOG protocol 98-12. Int. J. Radiar Oncol Biol. Phys. (2001) 51:29.
   Google Scholar
• WILLETT CG, SAFRAN H, ABRAMS RA, REGINE WF, RICH TA: Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int. J. Radiar Oncol Biol. Phys. (2003) 56\(Suppl. 4):31–37.
   Google Scholar
• EPELBAUM R, ROSENBLATT E, NASRALLAH S et al: Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J. &mg. Oncol (2002) 81(3):138–143.
   Web of Science ®Google Scholar
• IKEDA M, OKADA S, TOKUUYE K, UENO H, OKUSAKA T: A Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. BE J. Cancer (2002) 86(10):1551–1554.
   Web of Science ®Google Scholar
• MCGINN CJ, ZALUPSKI MM, SHUREIQI I et al.: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol (2001) 19(22):4202–4208.
   PubMed Web of Science ®Google Scholar
• HUANG NJ, HITTELMAN WN: Transient inhibition of chromosome damage repair after ionizing radiation by gemcitabine. Proc. Am. Assoc. Cancer Res. (2001) 36:612 (Abstract).
   Google Scholar
• CRANE CH, WOLFF RA, ABBRUZZESE JL et al: Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Smarm Oncol (2001) 28(3, Suppl. 10):25–33.
   PubMed Web of Science ®Google Scholar
• MASON KA, MILAS L, HUNTER NR et al.: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int. J. Radiar Oncol Biol. Phys. (1999) 44(5):1125–1135.
   PubMed Web of Science ®Google Scholar
• LI CP, CHAO Y, CHI KH et al: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int. I Radiar Oncol Biol. Phys. (2003) 57(1):98–104.
   PubMed Web of Science ®Google Scholar
• •This randomised trial showed that gemcitabine-based CRT was superior to 5-FU-based CRT in locally advanced PDA.
   Google Scholar
• HADDOCK MG, SWAMINATHAN R, ALBERTS SR, HAUGE MD, MARTENSON JA, FOSTER N: Phase II study of gemcitabine (Gem), cisplatin (Cis) and radiation therapy (RT) in patients with locally advanced pancreatic cancer: A North Central Cancer Treatment Group (NCCTG) study. 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004).
   Google Scholar
• Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer (1985) 56:2563–2568.
   PubMed Web of Science ®Google Scholar
• Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. Natl. Cancer Inst. (1988) 80:751–755.
   Google Scholar
• ISHII H, OKADA S, TOKUUYE K et al: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer (1997) 79(8):1516–1520.
   Google Scholar
• KAMTHAN AG, MORRIS JC, DALTON J et al: Combined modality therapy for stage II and stage III pancreatic carcinoma. I Clin. OncoL (1997) 15(8):2920–2927.
   Google Scholar
• KLAASSEN DJ, MACINTYRE JM, CATTON GE, ENGSTROM PF, MOERTEL CG: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern Cooperative Oncology Group study../. Clin. Oncol (1985) 3(3):373–378.
   Web of Science ®Google Scholar
• GRIFFIN JF, SMALLEY SR, JEWELL W et al.: Patterns of failure after curative resection of pancreatic carcinoma. Cancer (1990) 66(1):56–61.
   PubMed Web of Science ®Google Scholar
• GANSAUGE F, LINK KH, RILINGER N, KUNZ R, BEGER HG: Adjuvant regional chemotherapy in resected advanced pancreas carcinoma. Chirurg (1996) 67(4):362–365.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA O, OHIGASHI H, SASAKI Y et al: Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am. J. &mg. (1994) 168(4):361–364.
   Web of Science ®Google Scholar
• ISHIKAWA O, OHIGASHI H, IMAOKA S et al.: Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepatogastroenterology (1997) 44(18):1541–1546.
   PubMed Web of Science ®Google Scholar
• LINK KH, FORMENTINI A, GANSAUGE F, PAPACHRISTOV E, BEGERHG: Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection. Digestion (1997) 58(6):529–532.
   PubMed Web of Science ®Google Scholar
• BAKKEVOLD KE, ARNESJO B, DAHL O, KAMBESTAD B: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-- results of a controlled, prospective, randomised multicentre study. Eur. I Cancer (1993) 29A:698–703.
   PubMed Web of Science ®Google Scholar
• NEOPTOLEMOS JP, DUNN JA, STOCKEN DD et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 358(9293):1576–1585.
   PubMed Web of Science ®Google Scholar
• ••This large, partially 2 x 2 factorial,randomised trial suggested a survival benefit after adjuvant chemotherapy compared to surgery alone, but not after adjuvant CRT.
   Google Scholar
• NEOPTOLEMOS JP, STOCKEN DD, DUNN JA et al: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg. (2001) 234(6):758–768.
   PubMed Web of Science ®Google Scholar
• ALFIERI S, MORGANTI AG, DI GIORGIO A et al: Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer. Arch. Surg. (2001) 136(3)343–347.
   PubMed Web of Science ®Google Scholar
• JOHNSTONE PA, SINDELAR WF: Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy:correlations of a clinical trial. Int. J. Radiat. Oncol. Biol. Phys. (1993) 27(4):831–834.
   PubMed Web of Science ®Google Scholar
• LEE JH, WHITTINGTON R, WILLIAMS NN et al: Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int. J. Radiat. Oncol. Biol. Phys. (2000) 47(4)945–953.
   PubMed Web of Science ®Google Scholar
• MEHTA VK, FISHER GA, FORD JM et al.: Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int. I Radiat. Oncol. Biol. Phys. (2000) 48(5):1483–1487.
   PubMed Web of Science ®Google Scholar
• WILLETT CG, LEWANDROWSKI K, WARSHAW AL, EFIRD J, COMPTON CC: Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann. Surg. (1993) 217(2):144–148.
   PubMed Web of Science ®Google Scholar
• KLINKENBIJL HL, JEEKEL J, SAHMOUD T et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. (1999) 230:776–782.
   PubMed Web of Science ®Google Scholar
• Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer (1987) 59: 2006–2010.
   Google Scholar
• KALSER MH, ELLENBERG SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. (1985) 120:899–903.
   PubMed Web of Science ®Google Scholar
• ABRAMS RA, GROCHOW LB, CHAKRAVARTHY A et al.: Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int. J. Radiat. Oncol. Biol. Phys. (1999) 44(5):1039–1046.
   PubMed Web of Science ®Google Scholar
• PAULINO AC: Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure. Am. I Clin. Oncol. (1999) 22(5):489–494.
   PubMed Web of Science ®Google Scholar
• SOHN TA, YEO CJ, CAMERON JL et al: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. ./. Castrointest. Surg. (2000) 4(6):567–579.
   PubMed Web of Science ®Google Scholar
• KACHNIC LA, SHAW JE, MANNING MA, LAUVE AD, NEIFELD JP: Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int. J. Cancer (2001) 96(2):132–139.
   PubMed Web of Science ®Google Scholar
• BRESLIN TM, HESS KR, HARBISON DB et al.: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann. Surg. Oncol. (2001) 8(2):123–132.
   PubMed Web of Science ®Google Scholar
• HOFFMAN JP, MCGINN CJ, SZARKA C et al.: A Phase I study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM for patients with localized, resectable pancreatic adenocarcinoma (PAC). Proc. Am. Soc. Clin. Oncol. (1998) 17:283 (Abstract).
   Google Scholar
• SNADY H, BRUCKNER H, COOPERMAN A, PARADISO J, KIEFER L: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer (2000) 89(2):314–327.
   PubMed Web of Science ®Google Scholar
• COIA L, HOFFMAN J, SCHER R et al: Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int. I Radiat. Oncol. Biol. Phys. (1994) 30(1):161–167.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA O, OHIGASHI H, IMAOKA S et al: Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch. Surg. (1994) 129(10):1075–1080.
   PubMed Web of Science ®Google Scholar
• WANEBO HJ, GLICKSMAN AS, VEZERIDIS MP et al: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch. Surg. (2000) 135(1):81–87.
   PubMed Web of Science ®Google Scholar
• SOHN TA, LILLEMOE KD, CAMERON JL et al.: Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann. Surg. (1999) 229(3):393–400.
   PubMed Web of Science ®Google Scholar
• GNANT M, KUEHRER I, TELEKY B et al.: Neoadjuvant chemotherapy of locally advanced pancreatic cancer leads to 67% 3-year survival. 2004 Gastrointestinal Cancers Symposium, San Francisco, LA, USA (2004) 98 (Abstract).
   Google Scholar
• ASHAMALLA H, MOKHTAR B, DOSIK D, KRISHNAMURTHY M, COLELLA F: Hyperfractionated concomitant in-field boost with gemcytabine, paclitaxel followed by surgery in locally advanced pancreatic cancer. 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, USA (2004) 158 (Abstract).
   Google Scholar